ID: ALA4218389

Max Phase: Preclinical

Molecular Formula: C30H27FN6O5

Molecular Weight: 570.58

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1cc2c(cc1OC)Nc1ncnc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c1NC2

Standard InChI:  InChI=1S/C30H27FN6O5/c1-40-23-13-17-15-32-25-26(37-22(17)14-24(23)41-2)33-16-34-27(25)42-21-9-7-20(8-10-21)36-29(39)30(11-12-30)28(38)35-19-5-3-18(31)4-6-19/h3-10,13-14,16,32H,11-12,15H2,1-2H3,(H,35,38)(H,36,39)(H,33,34,37)

Standard InChI Key:  QRWMPHFMOUEZFY-UHFFFAOYSA-N

Associated Targets(Human)

CAKI-1 44928 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HepG2 196354 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

PANC-1 6144 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

PC-3 62116 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Hepatocyte growth factor receptor 10718 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 570.58Molecular Weight (Monoisotopic): 570.2027AlogP: 5.45#Rotatable Bonds: 8
Polar Surface Area: 135.73Molecular Species: NEUTRALHBA: 9HBD: 4
#RO5 Violations: 2HBA (Lipinski): 11HBD (Lipinski): 4#RO5 Violations (Lipinski): 3
CX Acidic pKa: 13.09CX Basic pKa: 3.86CX LogP: 4.43CX LogD: 4.43
Aromatic Rings: 4Heavy Atoms: 42QED Weighted: 0.20Np Likeness Score: -0.66

References

1. Huang D, Huang L, Zhang Q, Li J..  (2017)  Synthesis and biological evaluation of novel 6,11-dihydro-5H-benzo[e]pyrimido- [5,4-b][1,4]diazepine derivatives as potential c-Met inhibitors.,  140  [PMID:28938137] [10.1016/j.ejmech.2017.08.060]

Source